Female Infertility

Infertility is defined as failure to achieve a successful pregnancy after 12 months of regular, unprotected intercourse in a woman under 35 years of age, or after 6 months in a woman aged 35 or older — a deliberately age-adjusted trigger, since the pace of natural fertility decline itself accelerates after the mid-30s.^[1][2] Roughly 1 in 6 Canadian couples (an estimated 12-16%) experience infertility in any given year, a prevalence that has risen substantially from about 5% in the mid-1980s, driven in part by delayed childbearing.^[3]

A genuinely important framing point for both patients and the healthcare team: male factor contributes to roughly half of affected couples — solely responsible in about 20% of cases and a contributing factor in another 30-40% — so a proper evaluation is a couple-level investigation from the outset, not a female-only workup that only turns to the male partner after the female workup is exhausted.^[4]

What this chapter does, and honestly does not, cover

This chapter is scoped to what a community or specialty pharmacist can genuinely add to a patient's fertility journey: understanding the age-adjusted referral trigger and the basic diagnostic workup well enough to support a patient navigating it, counselling on the oral ovulation-induction agents pharmacists regularly dispense (letrozole and clomiphene), supporting patients on injectable gonadotropins and luteal-phase progesterone during a specialist-directed intrauterine insemination (IUI) or in vitro fertilization (IVF) cycle, reinforcing genuinely modifiable lifestyle factors, and offering non-judgemental, destigmatizing counselling around a diagnosis that carries a real psychosocial burden. It does not attempt to replicate an IVF stimulation protocol or embryology reference — selecting a stimulation protocol, titrating gonadotropin doses against real-time monitoring, and deciding on IUI versus IVF versus donor gametes are genuinely specialist (reproductive endocrinology and infertility) decisions, and this chapter says so plainly rather than fabricating a false sense of completeness in that territory.

Four leading categories, and one very common non-diagnosis

Once a couple meets the age-adjusted evaluation trigger (see Red Flags & Refer), the basic workup is designed to sort infertility into a small number of categories, each with a different downstream pathway:^[1]

Male factor

A semen analysis should be obtained early, in parallel with the female partner's workup rather than after it — a male factor is solely responsible in about 20% of infertile couples and contributory in another 30-40%, so together male factor is implicated in roughly half of all cases.^[4] Detailed male-factor evaluation and treatment (varicocele repair, hormonal therapy, surgical sperm retrieval) is urology/andrology territory and is not covered in this chapter.

Clinical presentation

Presentation is simply the couple's own account of time spent trying to conceive, plus clues pointing toward a specific category: irregular, infrequent, or absent menstrual cycles suggest ovulatory dysfunction; a history of PID, ruptured appendix, prior pelvic/tubal surgery, or known endometriosis (particularly with dysmenorrhea, dyspareunia, or chronic pelvic pain) suggests a tubal or pelvic factor; heavy or irregular bleeding, or a known history of fibroids or polyps, suggests a uterine factor. Many patients presenting with infertility have no localizing symptoms at all beyond the absence of pregnancy — this does not lessen the need for a systematic workup once the age-adjusted trigger is met.

• Age 35 or older — the single most important modifier of both natural fecundity and the workup timeline; risk continues to rise further after 40.^[2]
• Irregular, infrequent, or absent menstrual cycles (suggesting anovulation).
• Known or suspected PCOS, thyroid dysfunction, or hyperprolactinemia.
• Prior pelvic inflammatory disease, sexually transmitted infection, or known endometriosis.
• Prior pelvic, tubal, or abdominal surgery, including a ruptured appendix.
• Known or suspected uterine fibroids or endometrial polyps.
• A family history of early menopause, or other risk factors for primary ovarian insufficiency (e.g., prior pelvic radiation or gonadotoxic chemotherapy, certain genetic conditions).
• Known or suspected male-partner risk factors — prior groin/scrotal surgery or trauma, cryptorchidism, gonadotoxic exposure (chemotherapy, radiation, certain occupational exposures), or a previously abnormal semen analysis.
• Obesity or a very low body weight — both are associated with reduced natural fecundity.^[6]
• Smoking, and higher levels of alcohol consumption (more than 2 drinks/day).^[6]
• A personal or family history of infertility.

The basic couple-level fertility workup

Once the age-adjusted trigger is met (see Red Flags & Refer), a systematic, stepwise evaluation aims to identify all relevant contributing factors, starting with the least invasive tests for the most common causes.^[1]

Ovulation assessment

• Menstrual history is the simplest and most useful first step — cycles every 21-35 days are presumptive evidence of ovulation, with regular cycle length alone correctly predicting ovulatory status roughly 99.5% of the time in a non-hirsute woman.^[1]
• Mid-luteal serum progesterone, drawn about a week before expected menses (day 21 of an idealized 28-day cycle, adjusted for the patient's actual cycle length) — a level above 3 ng/mL is presumptive, sufficient evidence of recent ovulation.^[1]
• Urinary ovulation predictor kits (OPKs), which detect the mid-cycle LH surge, are a reasonable patient-directed option for timing intercourse, though false positives and negatives occur, particularly in PCOS.^[1]
• Basal body temperature (BBT) charting is no longer routinely recommended, especially when the menstrual history already indicates ovulatory cycles — it is a poor real-time predictor and adds burden without materially changing management.^[1]
• Endometrial biopsy to "date" the endometrium is no longer recommended for routine infertility evaluation — it cannot reliably distinguish fertile from infertile women.^[1]

Ovarian reserve testing

Ovarian reserve declines with age, and testing helps counsel a patient on expected response to ovulation-induction or ART — but a normal result does not guarantee fertility, and an abnormal result does not mean pregnancy is impossible; these tests should augment, not replace, age- and diagnosis-based counselling.^[1][2]

• Anti-Müllerian hormone (AMH) — can be drawn on any cycle day, making it the most practically convenient ovarian reserve test.
• Antral follicle count, by transvaginal ultrasound.
• Basal FSH and estradiol, drawn on cycle days 2-4.
• Not recommended: inhibin B and the clomiphene citrate challenge test — neither has demonstrated clinical utility for ovarian reserve assessment and both have been superseded by AMH and antral follicle count.^[1]

Tubal patency and uterine evaluation

• Hysterosalpingogram (HSG) — the standard test for tubal patency, also demonstrating basic uterine cavity architecture.
• Sonohysterography (saline infusion sonohysterogram) — high (over 90%) positive and negative predictive value for detecting intrauterine pathology such as polyps or submucous fibroids; often used to further characterize an abnormal HSG or ultrasound finding.^[1]
• Hysteroscopy — definitive diagnosis, and treatment in the same setting, for a confirmed intrauterine abnormality.
• Diagnostic laparoscopy with chromopertubation is not routine — it is generally reserved for a patient already undergoing surgery for another indication (e.g., suspected endometriosis requiring surgical diagnosis/treatment).^[1]

Male-partner evaluation

At least one semen analysis should be obtained at the outset of the couple's evaluation, in parallel with the female workup, given the high prevalence of a contributing male factor.^[1][4] Interpretation and further male-factor workup (repeat testing, hormonal evaluation, urology referral) is beyond the scope of this chapter.

When the complete workup is normal

A couple with regular ovulation, patent tubes, a normal uterine cavity, and a normal semen analysis is diagnosed with unexplained infertility — a genuinely common outcome with its own specialist-directed treatment ladder (see Choose Initial Treatment and Special Populations), not a diagnosis of exclusion that ends the conversation.^[5]

• Confirm whether the age-adjusted evaluation trigger has been met, and refer for formal workup promptly rather than defaulting to continued watchful waiting.
• Identify and, where genuinely modifiable, address an underlying cause — ovulatory dysfunction, a correctable endocrine abnormality, or a lifestyle factor — rather than proceeding straight to specialist-directed treatment for every patient.
• For anovulatory infertility with no other identified factor, achieve ovulation using first-line pharmacotherapy that a community/specialty pharmacist can genuinely support (letrozole, or clomiphene as an alternative).
• Support informed decision-making as a patient moves toward specialist-directed assisted reproduction — accurate counselling on what letrozole/clomiphene, gonadotropins, and IUI/IVF each actually involve, and honest acknowledgement of where specialist expertise takes over.
• Recognize and promptly escalate ovarian hyperstimulation syndrome and other red flags, rather than managing them symptomatically.
• Reinforce genuinely modifiable lifestyle factors (smoking cessation, alcohol moderation, weight optimization) as adjuncts to, not substitutes for, appropriate specialist care.
• Provide non-judgemental, destigmatizing support for the real psychological burden of infertility, and screen for and refer significant distress.

• Weight optimization — fertility is measurably reduced at both very low and elevated body weight; this is a genuinely pharmacist-actionable counselling point, and for a patient with obesity and PCOS-related anovulation specifically, cross-refer to the PCOS chapter's lifestyle-intervention and anti-obesity-pharmacotherapy guidance rather than duplicating it here.^[6]
• Smoking cessation — smoking has a substantial, well-documented adverse effect on fertility (in one large meta-analysis, smokers were significantly more likely to be infertile than non-smokers, odds ratio 1.60), plausibly through accelerated follicular depletion; smoking cessation support is one of the highest-yield pharmacist-led interventions available for this condition.^[6]
• Alcohol moderation — higher alcohol intake (more than 2 drinks/day) is best avoided while trying to conceive; the evidence for a meaningful effect of lighter, more moderate consumption is limited, so counselling should be proportionate rather than alarmist.^[6]
• Timed intercourse — for couples who cannot have frequent intercourse, fertility-awareness methods (tracking the fertile window via cycle timing or an ovulation predictor kit) can help time intercourse and may modestly shorten time to pregnancy; frame this as a reasonable adjunct, not a substitute for a workup once the age-adjusted trigger has been met.^[6]
• Psychosocial support — infertility carries a genuine and often under-recognized psychological burden, including anxiety, depression, grief, and relationship strain; approach every conversation with non-judgemental, destigmatizing language, avoid framing infertility as a personal failing, and proactively offer or refer for counselling/support resources rather than waiting for a patient to raise it.
• Preconception counselling — folic acid supplementation and routine preconception health optimization remain appropriate for anyone actively trying to conceive, regardless of infertility etiology or where they are in a workup (see Pharmacologic Treatment Options).

Primary ovarian insufficiency (POI)

Loss of normal ovarian function before age 40, presenting with irregular or absent periods and elevated gonadotropins on testing. POI needs prompt specialist (reproductive endocrinology) referral for both fertility counselling and long-term hormonal management — the fertility implications and hormone-therapy needs of POI differ meaningfully from typical perimenopausal ovarian decline, and are outside this chapter's scope beyond flagging the need for urgent referral.

Advanced maternal age (35 and older, particularly over 40)

Both natural fertility and assisted-reproduction success (with the exception of using donor eggs) decline significantly through the late 30s and 40s.^[2] Women in their 20s and 30s benefit from proactive counselling about this age-related decline as part of routine well-woman care — ideally well before they are actively trying to conceive — rather than learning about it only after a period of unsuccessful attempts.^[2] For a patient over 40, more immediate referral (rather than completing a full 6-month trial of time) is appropriate given the pace of decline at this age (see Red Flags & Refer).^[1]

Fertility preservation before gonadotoxic treatment

Any patient facing imminent chemotherapy, pelvic radiation, or another fertility-threatening treatment should be referred urgently — ideally before treatment starts — for a fertility-preservation consultation (e.g., oocyte or embryo cryopreservation). This is time-sensitive specialist territory; the pharmacist's role is recognizing the situation and prompting an urgent referral rather than delaying it to complete routine counselling.

Obesity-related and PCOS-related anovulatory infertility

PCOS is the leading cause of ovulatory-factor infertility. Full diagnostic criteria, lifestyle intervention, metformin dosing, and the complete letrozole/clomiphene ovulation-induction ladder (including combining clomiphene with metformin at a BMI of 30 kg/m2 or higher) are covered in the dedicated PCOS chapter and are not duplicated here — cross-reference that chapter for any patient whose infertility is PCOS-related.

Same-sex couples and single patients using donor gametes

The same age-adjusted evaluation principles generally apply to a same-sex couple or a single patient pursuing pregnancy with donor sperm, though the specific pathway (donor sperm insemination timing, reciprocal IVF, etc.) is specialist-directed and individualized to the patient's circumstances. Approach every patient's fertility goals with the same non-judgemental, supportive counselling regardless of relationship structure or route to conception.

Pregnancy after assisted reproduction

Continue specialist-directed luteal-phase progesterone support per the fertility clinic's own protocol once pregnancy is confirmed, and ensure the patient understands early pregnancy follow-up (including monitoring for multiple gestation, which is more common after ovulation induction or ART) is arranged through their fertility clinic or obstetric provider.

During ovulation induction (letrozole/clomiphene)

Cycle monitoring — typically transvaginal ultrasound, sometimes combined with serum estradiol — is arranged by the prescribing clinic to confirm follicular response and time intercourse or insemination; this is not a community-pharmacy monitoring task. The pharmacist's practical monitoring role at each refill is confirming a negative pregnancy test before the next cycle begins, asking about early OHSS symptoms (bloating, pelvic discomfort), and confirming the patient is taking the medication on the correct cycle days.

During gonadotropin/ART cycles

Monitoring intensity (serial ultrasound and estradiol) is entirely specialist-directed and individualized cycle-by-cycle. Reinforce that any rapid bloating, significant abdominal pain, nausea/vomiting, shortness of breath, or marked rapid weight gain during or shortly after a stimulated cycle needs urgent assessment by the treating fertility clinic (see Red Flags & Refer) rather than being managed symptomatically.^[7]

Longitudinal follow-up

For a patient who has met the age-adjusted referral trigger but not yet completed a specialist workup, follow up on whether the referral was actually completed — age-sensitive fertility windows make delayed follow-through a genuine clinical concern, not just an administrative gap. For a patient already established with a fertility specialist, keep pharmacy counselling complementary to, not duplicative of, the specialist's own monitoring plan.

1. Ovulation not achieved on letrozole after standard dose escalation (up to 7.5 mg/day): reassess cycle-day timing and adherence before concluding failure; if genuinely refractory, the prescriber may add metformin or switch to clomiphene plus metformin, particularly at a BMI of 30 kg/m2 or higher — see the PCOS chapter's own treatment-failure pathway for detail, since this scenario is most often PCOS-related.^[8]
2. Ovulation achieved but no pregnancy after an adequate trial (commonly around 5-6 ovulatory cycles) of oral ovulation induction: refer for specialist-directed escalation to gonadotropins, IUI, or IVF rather than continuing oral agents indefinitely.
3. An abnormal HSG, ovarian reserve test, or semen analysis identified during the initial workup: refer promptly to the appropriate specialist (reproductive endocrinology for a female factor, urology/andrology for a male factor) rather than trialing empiric ovulation induction alone while the actual identified factor goes unaddressed.
4. Age 35 or older with any additional risk factor, or age over 40 regardless of other findings: escalate referral urgency — do not insist on completing a full standard-duration trial of time first (see Red Flags & Refer).
5. OHSS symptoms reported during or after a stimulated cycle: escalate urgently to the treating fertility clinic or emergency care as appropriate — this is not a pharmacist-managed symptom (see Red Flags & Refer).^[7]
6. Unexplained infertility after a complete, normal workup: refer for the specialist-directed treatment ladder (expectant management, IUI, ovarian stimulation, or IVF) rather than treating a normal workup as a dead end.^[5]

• Applying a blanket 12-month waiting period regardless of age or known risk factors — age 35 or older shortens the trigger to 6 months, and age over 40 or an additional red flag warrants more immediate referral rather than a full trial of time.
• Treating the workup as female-only and delaying a semen analysis until the female evaluation is "exhausted" — male factor contributes to roughly half of couples' infertility and should be assessed in parallel from the outset.
• Ordering an inhibin B level or a clomiphene citrate challenge test for ovarian reserve — neither has demonstrated clinical utility; AMH and antral follicle count are the current standard tests.
• Treating a normal AMH/antral follicle count as a guarantee of fertility, or an abnormal result as a guarantee of infertility — ovarian reserve tests should augment, not replace, age- and diagnosis-based counselling.
• Dispensing or refilling letrozole or clomiphene without confirming a negative pregnancy test for the upcoming cycle.
• Omitting OHSS and multiple-pregnancy counselling when starting a patient on any ovulation-induction or gonadotropin therapy — both are genuine, not exotic, risks that patients deserve to hear about upfront.
• Attempting to independently interpret or adjust a specialist-titrated gonadotropin dose or trigger-shot timing — this is real-time, monitoring-driven, specialist-directed care, and pharmacist scope here is technique counselling and symptom recognition, not dosing.
• Treating "unexplained infertility" as a reassuring non-diagnosis rather than a genuine diagnosis with its own specialist-directed treatment ladder.
• Using judgemental or minimizing language ("just relax and it will happen," "have you tried...") that adds to the real psychological burden of infertility rather than offering non-judgemental support.
• Missing the opportunity to counsel a patient of reproductive age proactively about age-related fertility decline during routine well-woman visits, rather than only after they have already struggled to conceive.

How to use this table: doses are adult obstetric/gynecologic doses specific to ovulation induction and assisted reproduction and require patient-specific, and often clinic-protocol-specific, confirmation. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Oral Ovulation Induction

First-line and alternative agents for anovulatory infertility with no other identified factor. Confirm a negative pregnancy test before each new cycle — both agents are contraindicated once pregnancy is confirmed.^[8]

Injectable Gonadotropins and Trigger — Specialist-Directed IUI/IVF Cycles

Dose selection and protocol are entirely specialist-directed and individualized cycle-by-cycle based on real-time monitoring. Pharmacist role: injection-technique counselling, storage, and OHSS symptom recognition — not dosing.^[7]

Luteal-Phase Support — Specialist-Directed ART Cycles

Following IUI or IVF, per the fertility specialist's own protocol; interrupting without specialist direction can jeopardize an established pregnancy.

Preconception Adjunct — All Patients Actively Trying to Conceive

Appropriate regardless of infertility etiology or workup stage.

Evidence note: male-partner infertility risk factors and semen analysis are referenced throughout this chapter but are not detailed in this drug table — male-factor pharmacotherapy is urology/andrology-directed and outside this chapter's scope.^[4]